Panacea Biotec Pharma redeems entire outstanding NCDs

Image
Capital Market
Last Updated : Mar 04 2022 | 9:31 PM IST
Panacea Biotec announced that its material wholly owned subsidiary, . Panacea Biotec Pharma (PBPL) has fully redeemed the entire outstanding NCDs aggregating Rs 754.44 crore together with redemption premium of Rs 343.63 crore, out of the funds received by it in consideration of the sale of domestic pharmaceutical formulations brands in Nepal and India held by PBPL.

As a result, PBPL has now become a debt free company.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 04 2022 | 9:11 PM IST

Next Story